Viiv is promoting findings for their long acting PrEP & HIV meds. They promote data that supports the efficacy of & preference for their long acting meds; Apretude, Vocabria & Cabenuva. These injections aren't as long acting as Gilead's Lenacapavir. There may be other reasons to prefer Viiv's options.
The company has also pledged to let some low income countries manufacture & market generic versions of these meds. Making these drugs far more affordable. This & Gilead's similar pledge were most likely due to public pressure & the US ceasing funding to HIV programs.
That's all for now, take care.
Cya...
No comments:
Post a Comment